Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: An SDOC Analysis
Overview
Authors
Affiliations
Objectives: Analyses performed by the Sarcopenia Definitions and Outcomes Consortium (SDOC) identified cut-points in several metrics of grip strength for consideration in a definition of sarcopenia. We describe the associations between the SDOC-identified metrics of low grip strength (absolute or standardized to body size/composition); low dual-energy x-ray absorptiometry (DXA) lean mass as previously defined in the literature (appendicular lean mass [ALM]/ht ); and slowness (walking speed <.8 m/s) with subsequent adverse outcomes (falls, hip fractures, mobility limitation, and mortality).
Design: Individual-level, sex-stratified pooled analysis. We calculated odds ratios (ORs) or hazard ratios (HRs) for incident falls, mobility limitation, hip fractures, and mortality. Follow-up time ranged from 1 year for falls to 8.8 ± 2.3 years for mortality.
Setting: Eight prospective observational cohort studies.
Participants: A total of 13,421 community-dwelling men and 4,828 community-dwelling women. MEASUREMENTS Grip strength by hand dynamometry, gait speed, and lean mass by DXA.
Results: Low grip strength (absolute or standardized to body size/composition) was associated with incident outcomes, usually independently of slowness, in both men and women. ORs and HRs generally ranged from 1.2 to 3.0 for those below vs above the cut-point. DXA lean mass was not consistently associated with these outcomes. When considered together, those who had both muscle weakness by absolute grip strength (<35.5 kg in men and <20 kg in women) and slowness were consistently more likely to have a fall, hip fracture, mobility limitation, or die than those without either slowness or muscle weakness.
Conclusion: Older men and women with both muscle weakness and slowness have a higher likelihood of adverse health outcomes. These results support the inclusion of grip strength and walking speed as components in a summary definition of sarcopenia. J Am Geriatr Soc 68:1429-1437, 2020.
Fielding R, Dao M, Cannon K, Desvarieux M, Miller S, Gimness M J Cachexia Sarcopenia Muscle. 2025; 16(2):e13750.
PMID: 40026058 PMC: 11873539. DOI: 10.1002/jcsm.13750.
Dietary Patterns, Kidney Function, and Sarcopenia in Chronic Kidney Disease.
Kim J, Yang S Nutrients. 2025; 17(3).
PMID: 39940262 PMC: 11821004. DOI: 10.3390/nu17030404.
Lahr P, Carling C, Nauer J, McGrath R, Grier J Hearts (Basel). 2025; 5(3):275-287.
PMID: 39897455 PMC: 11784985. DOI: 10.3390/hearts5030020.
Burton A, Drew S, Cassim B, Jarjou L, Gooberman-Hill R, Noble S Wellcome Open Res. 2025; 8():261.
PMID: 39822313 PMC: 11736110. DOI: 10.12688/wellcomeopenres.19391.1.
Cruz J, Pereira L, Steffens D, Vieira Carvalho A, Drummond-Lage A Ann Transl Med. 2025; 12(6):114.
PMID: 39817248 PMC: 11729810. DOI: 10.21037/atm-24-128.